Experiment Overview
| Repository ID: | FR-FCM-ZZSC | Experiment name: | OMIP-037: 16-color panel to measure inhibitory receptor signatures from multiple human immune cell subsets | MIFlowCyt score: | 29.25% |
| Primary researcher: | Anna Belkina | PI/manager: | Anna Belkina | Uploaded by: | Anna Belkina |
| Experiment dates: | 2015-06-20 - 2015-08-31 | Dataset uploaded: | Jun 2016 | Last updated: | Oct 2016 |
| Keywords: | [T cell] [NK cells] [OMIP] [checkpoin inhibitors] | Manuscripts: | [27706900] |
|
|
| Organizations: |
Boston University School of Medicine, Flow Cytometry Core Facility, Boston, MA (USA)
|
||||
| Purpose: | The panel was developed to determine the combinational inhibitory receptor expression (“IR signatures”) of CD4+ T cells, CD8+ T cells, Natural Killer (NK) cells, invariant Natural Killer T (iNKT) cells, and gamma delta (γδ) T cells from individual human samples. The inhibitory receptors measured are PD-1, TIM-3, CD160, LAG-3, and TIGIT. The activation marker CD137 (4-1BB) is also included in the panel, as is IL-7Rα (CD127). This panel works well with cryopreserved PBMC from healthy and HIV-infected individuals well as fresh tumor specimens. For optimum performance of this panel with digested tumor specimens, the pan-lymphocyte marker CD45 is included (swapped for LAG-3). Other tissues/sample types have not yet been evaluated. Also, a modification of this panel has been optimized that includes CD45RO and CD25 in place of CD160 and CD137. | ||||
| Conclusion: | See paper (https://www.ncbi.nlm.nih.gov/pubmed/27706900) | ||||
| Comments: | See paper (https://www.ncbi.nlm.nih.gov/pubmed/27706900) | ||||
| Funding: | Internal fundng | ||||
| Quality control: | See paper (https://www.ncbi.nlm.nih.gov/pubmed/27706900) | ||||
